Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common and impairing neurodevelopmental disorder in which genetic factors play an important role. DNA sequencing of parent-child trios provides a powerful approach for identifying de novo (spontaneous) variants, which has led to the discovery of hundreds of clinically informative risk genes for other neurodevelopmental disorders but has yet to be extensively leveraged in studying ADHD. Here, we conducted whole-exome DNA sequencing in 152 parent-child trios with ADHD and demonstrate for the first time a significant enrichment of rare and ultra-rare de novo protein-truncating variants and missense variants predicted to be damaging in ADHD cases compared to unaffected controls. Combining these results with a large independent case-control DNA sequencing cohort (3,206 ADHD cases and 5,002 controls), we identify lysine demethylase 5B (KDM5B) as a high-confidence risk gene for ADHD as well as two likely risk genes. We estimate that 862 genes contribute to ADHD risk. Finally, using our list of genes harboring ultra-rare de novo damaging variants, we show that these genes overlap with previously reported risk genes for other neuropsychiatric conditions in both DNA sequencing and genome-wide association studies. We also show that these genes are enriched for several canonical biological pathways, suggesting early neurodevelopmental underpinnings of ADHD. Overall, this work provides critical new insight into the biology of ADHD and demonstrates the discovery potential of DNA sequencing in larger parent-child trio cohorts.
Significance statement Given the important role of genetic factors in the development of attention-deficit/hyperactivity disorder (ADHD), research aimed at identifying risk genes can provide critical insight into underlying biological processes. We conducted whole-exome DNA sequencing in parent-child trios with ADHD, showing that these children have a significantly greater rate of rare and ultra-rare de novo gene-damaging mutations compared to unaffected controls, expanding our understanding of the genetic landscape of ADHD. We then use this information to identify KDM5B as a high-confidence risk gene for ADHD and highlight several enriched biological pathways. This work advances our etiologic understanding of ADHD and illustrates a previously unexplored path for risk gene discovery in this common neurodevelopmental disorder.
Competing Interest Statement
The authors declare no conflict of interest. In the past 3 years, GVP has been consultant, advisory board member, and/or speaker for Ache, Abbott, Apsen, Medice, Novo Nordisk, Pfizer and Takeda. GVP also receives royalties from Editora Manole.
Funding Statement
This work was supported by a Klingenstein Third Generation Foundation ADHD Fellowship grant (E.O.), a Yale Child Study Center Faculty Development Award (T.V.F.), and the Allison Family Foundation (T.V.F.). Brazilian samples were recruited and collected with support from Sao Paulo Research Foundation (FAPESP, grant 2016/22455-8). E.O. was supported by the National Institute of Mental Health grants R25MH077823, T32MH018268, and K08MH128665. L.C.F. was supported by grant #2021/08540-0, Sao Paulo Research Foundation (FAPESP). J.P. was supported by the Bradley Hospital COBRE Center for Sleep and Circadian Rhythms in Child and Adolescent Mental Health (P20GM139743, PI Carskadon).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee/IRB of Universidade de Sao Paulo gave ethical approval for this work. The ethics committee/IRB of Centre for Addiction and Mental Health gave ethical approval for this work. The ethics committee/IRB of University of Toronto and Mental Health gave ethical approval for this work. The ethics committee/IRB of Florida International University gave ethical approval for this work. The ethics committee/IRB of Yale University waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Major classification: biological sciences
Minor classification: genetics
Data Availability
All data produced in the present work are contained in the manuscript.
